---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-016301"
form_type: "8-K"
ticker: "OLMA"
cik: "0001750284"
company_name: "Olema Pharmaceuticals, Inc."
filed_at: "2023-10-10T23:59:59+00:00"
generated_at: "2026-06-10T02:34:39.467690+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Olema and Novartis expand Phase 1/2 combo study of palazestrant + ribociclib to ~60 patients

## Summary
- Amendment adds ~30 patients to dose expansion, increasing study size to about 60 total.
- Phase 1b dose escalation completed; Phase 2 expansion at 120 mg palazestrant + 600 mg ribociclib.
- Expanded dataset may support regulatory path for a first-line pivotal trial in ER+ breast cancer.
- Collaboration originally signed July 2020; amended in January 2022 and now expanded again.
- Olema (OLMA) and Novartis (NVS) partner on this combination trial.

## SEC filing metadata
- accession: 0001558370-23-016301
- form_type: 8-K
- ticker: OLMA
- cik: 0001750284
- company_name: Olema Pharmaceuticals, Inc.
- filed_at: 2023-10-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1750284/000155837023016301/0001558370-23-016301-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1750284/000155837023016301/olma-20231009x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-016301
- JSON: https://secwatch.observer/filing/0001558370-23-016301.json
- Plain text: https://secwatch.observer/filing/0001558370-23-016301.txt

## Key facts
- Material Agreements
  Olema Pharmaceuticals, Inc. amended Amendment No. 1 to Amended and Restated Clinical Collaboration and Supply Agreement with Novartis Institutes for BioMedical Research, Inc. (effective 2023-10-09).
  - Action: amendment
  - Agreement: collaboration
  - Counterparty: Novartis Institutes for BioMedical Research, Inc.
  - Effective: 2023-10-09
  source text: On October 9, 2023, Olema Pharmaceuticals, Inc. (the “Company”) entered into an Amendment No. 1 to Amended and Restated Clinical Collaboration and Supply Agreement (the “Amendment”) with Novartis Institutes for BioMedical Research, Inc. (“Novartis”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1750284/000155837023016301/0001558370-23-016301-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.